Pirfenidone regulates obesity-related renal injury through the SIRT3 signaling pathway
International Immunopharmacology · 2025
DOI: 10.1016/j.intimp.2025.115709 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2025. Verfasst von Shan Yang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, The Second Affiliated Hospital, Chongqing Medical University, Chongqing 400010, China. Hauptthemen laut MEDLINE: Obesity, Sirtuin 3, Pyridones. Die Arbeit nennt 69 Literaturangaben. Gefördert von: Chongqing Natural Science Foundation, Chongqing Municipal Education Commission.
Abstract (Originalsprache)
OBJECTIVE: Pirfenidone (PFD) has been used to treat kidney fibrosis. However, the effects of PFD on obesity-related kidney injury and the underlying mechanisms are still poorly understood. METHODS: Male C57BL/6 J mice were fed a high-fat diet (HFD) for 20 weeks to induce kidney injury, and PFD was added to the feed of the mice in the PFD group beginning at 8 weeks. The controls were fed a normal control diet (NCD), and half of the mice were similarly treated with PFD. Indicators associated with lipid metabolism and kidney injury were assessed in vivo. Furthermore, human proximal tubular epithelial (HK-2) cells and human primary renal proximal tubule epithelial cells (PTECs) were incubated with palmitate (PA) and PFD, to investigate the effect of PFD on tubule cell injury in vitro. Single-cell sequencing analysis, molecular docking, and coimmunoprecipitation were subsequently used to explore the mechanisms of PFD action. RESULTS: PFD ameliorated metabolic abnormalities, inflammatory responses and oxidative stress induced by an HFD. PFD alleviated renal fatty acid oxidation and injury indicators in the HFD-fed mice and PA-treated renal tubular cells. PFD reversed the HFD/PA-induced decrease in SIRT3 protein expression. Moreover, transfection with si-SIRT3 abolished the beneficial effects of PFD on kidney injury and lipid metabolism in HK-2 cells. CONCLUSION: In summary, our data revealed that PFD could mitigate obesity-related kidney injury in a SIRT3-dependent manner.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, The Second Affiliated Hospital, Chongqing Medical University, Chongqing 400010, China.
- Department of Gastrointestinal Surgery, Chongqing University Qianjiang Hospital, 409000, China.
- Department of Urology and Andrology Laboratory, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China.
- Department of Endocrinology, Chongqing University Qianjiang Hospital, 409000, China.
- Department of Endocrinology, Chongqing University Qianjiang Hospital, 409000, China. Electronic address: dengwenzhen@cqu.edu.cn.
- Department of Nephrology, The Second Affiliated Hospital, Chongqing Medical University, Chongqing 400010, China. Electronic address: lxh@hospital.cqmu.edu.cn.
Förderung
- Chongqing Natural Science Foundation
- Chongqing Municipal Education Commission
Zitieren
APA
Yang, S., Chen, C., Xiong, Y., Ling, J., Chen, L., Wang, C., Zhang, X., Yi, J., Deng, W., & Liao, X. (2025). Pirfenidone regulates obesity-related renal injury through the SIRT3 signaling pathway. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2025.115709
Vancouver
Yang S, Chen C, Xiong Y, Ling J, Chen L, Wang C, et al. Pirfenidone regulates obesity-related renal injury through the SIRT3 signaling pathway. International Immunopharmacology. 2025. doi:10.1016/j.intimp.2025.115709
BibTeX
@article{Yang2025,
author = {Yang, Shan and Chen, Cheng and Xiong, Yang and Ling, Jiaxiu and Chen, Lijuan and Wang, Chunxia and Zhang, Xiaoyu and Yi, Jixiu and Deng, Wenzhen and Liao, Xiaohui},
title = {Pirfenidone regulates obesity-related renal injury through the SIRT3 signaling pathway},
journal = {International Immunopharmacology},
year = {2025},
doi = {10.1016/j.intimp.2025.115709}
}
EUVIMED